TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

NCT00665847 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1

Interventions

DRUG: Etravirine (TMC125)
DRUG: Optimized background regimen (OBR)

Sponsor

Tibotec Pharmaceuticals, Ireland